Hot flashes are sudden sensations of heat, often accompanied by sweating and flushing, primarily affecting menopausal women. They account for around half of women aged 40 to 64 worldwide, significantly impacting quality of life. There is a high unmet clinical need for better therapies, as current treatment options, such as hormone replacement therapy, may carry risks. The growing focus on non-hormonal hot flashes therapeutics, including neurokinin receptor antagonists and selective estrogen receptor modulators, is driving pipeline growth.
The Hot Flashes Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into hot flashes therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hot flashes. The hot flashes report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hot flashes pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hot flashes treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hot flashes.
Hot flashes are sudden, intense feelings of heat, often accompanied by sweating, flushing, and chills. They occur due to hormonal fluctuations, particularly the decline in estrogen during menopause. This affects the hypothalamus, the body’s temperature regulator, leading to vasodilation and excessive heat dissipation, causing discomfort and disruption in daily life.
Hot flashes treatment includes hormone replacement therapy (HRT), the most effective option, but it carries potential risks. Non-hormonal alternatives like SSRIs, gabapentinoids, and neurokinin receptor antagonists (e.g., Fezolinetant) offer relief. Lifestyle modifications, cognitive behavioral therapy, and herbal supplements such as black cohosh also help manage symptoms with varying efficacy.
Hot flashes affect 75%-80% of menopausal women in the United States and 24% of Japanese women, peaking at ages 50-54. Globally, over 50% of women aged 40–64 experience vasomotor symptoms (VMS), including hot flashes. In Europe, 31%-52% of postmenopausal women report moderate to severe VMS. Advancements in hot flashes therapeutic products, including neurokinin receptor antagonists, are driving pipeline growth.
This section of the report covers the analysis of hot flashes drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total hot flashes clinical trials.
The drug molecule categories covered under the hot flashes pipeline analysis include small molecules, monoclonal antibodies, peptides, neurokinin receptor antagonists, and gene therapies. The hot flashes report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hot flashes.
The EMR report for the hot flashes drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hot flashes therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hot flashes clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hot flashes. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hot flashes drug candidates.
Fezolinetant, developed by Astellas Pharma Inc., is being evaluated in a Phase III study to assess its efficacy and safety in reducing hot flashes in Japanese menopausal women, compared to a placebo. The study is expected to be completed by March 2026, with around 390 participants enrolled.
Elinzanetant, an investigational drug developed by Bayer, is being studied in the Phase III OASIS-4 trial to evaluate its efficacy and safety in treating hot flashes caused by anti-cancer therapy in women with or at high risk for hormone-receptor-positive breast cancer. The drug is a selective neurokinin-3 (NK3) receptor antagonist designed to reduce hot flashes without affecting hormone levels. The study, involving approximately 473 participants, is expected to be completed by December 2026 and compares Elinzanetant to a placebo.
NOE-115 is being evaluated in a Phase 2a study to assess its safety, tolerability, and preliminary efficacy in women experiencing moderate to severe vasomotor symptoms (hot flashes) due to menopause. The study, involving approximately 24 participants, is expected to be completed by April 30, 2025. This multicenter, open-label trial seeks to assess NOE-115 as a potential therapeutic product for hot flashes.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Hot Flashes Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for hot flashes. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hot flashes collaborations, regulatory environments, and potential growth opportunities.
Hot Flashes Epidemiology Forecast
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share